Key Points
- A Michigan judge has ruled that a lawsuit against Gilead Sciences, the maker of remdesivir (Veklury), can proceed despite Gilead's claim of PREP Act protection.
- The lawsuit stems from a man's use of contaminated remdesivir at St. Joseph Mercy Chelsea Hospital, leading to health problems and his eventual death.
- The recalled batch of remdesivir was contaminated with glass particles, with Gilead acknowledging the potential for serious health issues.
- The court's decision challenges the PREP Act's immunity provision and allows the case to move forward, possibly holding Gilead accountable for negligence.
- The judge noted that the contamination compromised the drug's status as a covered countermeasure under the PREP Act.
- This ruling could have implications for addressing claims involving other countermeasures covered by the PREP Act, though its impact on mRNA vaccine cases is uncertain.
Read more at childrenshealthdefense.org
